TD Cowen analyst Joshua Jennings lowered the firm’s price target on Insulet to $300 from $350 and keeps an Outperform rating on the shares. The firm posted another solid quarter which enabled another round of sales guidance raises with full-year revenue growth now expected at 22-25%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD: